#578 Engineering Longevity: Dr. Bill Andrews on Telomeres, Genetics, and the Future of Aging

Mehmet: [00:00:00] Hello and welcome back to episode of the CT O Show with Mehmet today are very pleased. Joining me from the US from Nevada, Dr. Bill Andrews. Dr. Bill, he is a long time, I would say veteran in the space of, uh, curing aging genetics. He led discoveries of human aries, the enzymes that being called by breakthrough in understanding how we age at the zero level, and he holds over 50 patents related to genetics and anti-aging innovations.

I don't like to steal much from my guests usually, and this is why I usually pass it to them directly. But Dr. Bill, we're gonna talk about a topic, which maybe for the audience, they will see it not much related to technology, but I think it's a very important topic from both scientific perspective and from life perspective.

We're gonna talk about aging and, and curing aging, and this is why, again, [00:01:00] I like to hear it from you. Tell us more about you, your, your background and what you're currently up to, and then we can start the conversation from there. So the floor is yours. 

Bill: Yeah. Well first I, I've been trying to understand aging my entire life, um, just so that I could do something about it.

Uh, I, I guess even all through high school, college, graduate school, uh, I've been focused on building an arsenal of tools that I thought I needed to know in order to figure out, you know, what aging is and why we age and how we age, uh, and then therefore how not to age. Um, but the, uh. I, I've just, uh, I, you know, I would take course, I, like, I got a bachelor's degree in biology, but I also got a bachelor's degree in experimental psychology because I complained to the school, I said, Hey, biology is not teaching me how to be a scientist.

And they said, well, do, do experimental psychology too. So I did, I double majored. [00:02:00] Um, and, uh, I learned a lot about how to really be a scientist, which most biologists don't have any experience doing. Uh, so like learning things like experimental design, uh, data analysis, construct validity, statistical theory, all these things or tools I developed for myself taking classes that most scientists don't have.

So it, it kind of gave me an edge. And then when I went to graduate school, I, I essentially got two PhDs. One in, uh, molecular genetics, and the other one in population genetics. Um, population genetics is the study of. Evolution, but not the what and when more is the why and how, why did we evolve things and how did we evolve things?

That's, that's that, those are the kind of things that I really needed to know because I, I really wanted to know why did, if aging is so bad, why didn't we ever evolve away not to age? Okay. Well, I, I know [00:03:00] why exactly now. Okay. And but, uh, molecular genetics was, that was the study of, you know, how to control our own evolution where, you know, where did evolution fail us?

How, how can I correct the problems that evolution Cause for us, because lemme just cover that really shortly. Uh, evolution is all about survival of the species, not the individual. Okay. So it is like, things that have occurred, we've evolved has been are things that allowed the. The species to survive rapidly changing environments.

And one of those things turns out to be, uh, elimination of the longer lived. I don't like using old because life's about living, not getting old. Elimination of the longer lived, the longer lived being anybody that has raised their young is longer lived. Okay? And so once you have raised your young, it's better for the species to get [00:04:00] rid of you because there's more diversity created within the species by let allowing the offspring to interbreed as opposed to the parents re breeding.

And the more diversity there is within a species. The better chance that at least some of the members of the species will survive the rapidly changing environment. Remember, in order for a species to survive, not all, all members, not all individuals within the species have to survive just a few. And that's, that's what, that's what evolution's all about, is making certain that there's at least a few that are gonna have some kind of diversity that's gonna make them survive when other members of the same species will not survive.

So, so that's why we age and we we're smarter than evolution now. And so I'm just trying to make certain that we can fix that problem and, and, and undo it. But, you know, it's, it's a, it's a struggle. It's a lot of work to do that. 

Mehmet: Of course, indeed. It's a lot of work. And thank you [00:05:00] again, uh, for being here with me today.

Now one thing, you know, from the introduction you just mentioned, which sparked, you know, some curiosity, um. We've been searching for a way to overcome this for a long time. Like since, I don't know, s of year right now, why we didn't yet, you know, find, because you, you talked now about evolution, and I know I'm going a little bit philosophical here as well.

Um, why do we need this bill? Like why we, we want, is it like to be without? And I like when you said, we don't, we don't want to get old. We want to live, but is it more about staying as much as possible healthy, or is it about. Staying here as long as [00:06:00] possible, whatever it takes. 

Bill: You know, I get asked that question a lot, but I, I tell you the truth, there isn't a person in the field of trying to, in the longevity field that is not trying to increase our health span.

Okay? It's, it's, that's priority. Nobody's, nobody wants us to live a long time and be in hospital beds with tubes sticking out of us. The priority is to keep us healthy as long as possible so that we can play tennis, dance, have the time of our lives, even when we're 150 years old. Uh, it, it's, so, yeah. So the priority is, the goal here is to make us live healthy as long as possible.

Mehmet: Living healthy as long as possible. Now, I want to go to the root cause, like I'm engineer by trade and, you know, one of the thing they, they train us to do. When, when we want to solve a problem, uh, [00:07:00] is first to understand the problem, understand the root cause of that problem so it doesn't happen again. So I'm curious to know, maybe some people will, will have like some general known answers that they hear, you know, maybe on the internet, sometimes maybe from fellow doctors in the, and the practitioners in the field.

But really what's the cause that we have all these diseases as we, you know, go, I would not use older, like as we go forward in our life. 

Bill: Well, this is what I've been studying my entire life, and I'll tell you that every theory I've ever heard of makes no sense. Okay? So I have had to just start from scratch and figure it all out for myself, and that's what my lifelong career has been all about.

But, but I I, but to explain it, simply, aging begins with wear and tear. Okay? [00:08:00] But it's not just wear and tear. We aren't like old trucks sitting in a field. That ex exposure to sun and wind and rain causes us to suffer from a lot of wear and tear. Humans have the ability. To repair our wear and tear. Okay.

We, we have cell division. Okay. Whereas trucks don't we, so when, when, if you think of like an organ or tissue or anything like that, including even the skin, there's cells on the surface that are called the frontline cells. And then there's cells deeper inside the skin that are kind, kind of called the reserve cells, which include our stem cells and our progenitor cells.

Um, but when we get damaged like a sunburn or something like that, or, or we drink some toxic solution, it kills our liver cells or kidney cells and things like that, we have other cells that can divide to replace those killed frontline cells. Okay. And, uh. [00:09:00] So given that we shouldn't age, okay, because we can constantly repair ourselves.

But here's the problem, and this is true for humans, dogs, cats, horses, sheep, pig, and deer, uh, and primates except for lemurs. Uh, but it's not true for rodents, uh, what I'm about to say. And that's that our cells can only divide a limited number of times, and that's not a theory, it's a fact. Okay? Any, any scientist working on studying human cells and petri dishes in a research when they buy cells from a vendor, the catalog they look at with, say what?

With the, the age of the donor and how many times those cells have divided since they were obtained from that donor. And you can calculate from that how many more times. Your, the cells you're working with can divide before you can't do any more research with 'em. And so the more times they have remaining to divide, the more you pay for the [00:10:00] cells.

So we all know anybody working on the cells knows that this is a real thing about human cells. Same with dogs, cats, and horses and the other animals. I mentioned that they can only divide a certain number of time and let that sink in for a second because that really says we have a limit to our lifespan.

Okay? Wear and tear there is kind of like some timeframe or synchrony or whatever you want to call it to are even wear and tear because some wear and tear is un unavoidable. Okay? Let's say blood flowing through our veins, okay? That causes wear and tear of the endothelial cells that line our blood vessels.

There's nothing we can do that about that. That's just gonna happen. And it turns out that the frontline cells along our blood vessels actually. Survive about two and a half years on average. And so that kind of like, and we can speed that up. We can't make it go [00:11:00] slower than two and a half years because we'd have to stop our blood flow to do it and that would kill us.

Okay, so we, so we do have this, this timeframe, this clock of wear and tear. But, but when we're young, we have no problems 'cause we can have other cells divide to replace those, but they eventually run out of their cell division. And what I, what I, when I was still in college and I was running anti-aging clubs, we would have discussions on how could a cell know how many times it has divided and how many more times it can divide.

And we knew cells don't have brains. So what's going on here? And we, we came up with this idea that the only explanation is that there has to be something inside of our cells that's like, and this is gonna sound silly. Ride tickets at an amusement park. Okay, so ev you go to an amusement park, your mother gives you a bunch of tickets, and you go on a ride and you lose a ticket.

You go on another ride, you lose another ticket. You can always look at the number of tickets you have, you know, how many times, [00:12:00] how many rides you've gone, how many rides you have left. There had to be something in our cells 'cause there's no other biochemical mechanism that we could imagine that could count.

So it was something had to be eliminated every time our cells divided. Well, we, it, it took me, uh, I'd say 20 years, maybe 15 years after that to figure out what that is. And we now know it's telomeres. The very tips of our chromosomes. That's where our ride tickets are. Okay. When we are first conceived as a single cell embryo.

We have 100 ride tickets at the end of our chromosomes. When our, when our, when our cell divides to become two cells, each of those cells have 99 ride tickets. And then when they divide, their daughter cells have 98. Okay. When we're first conceived or when first born, we're already down to where we only have 50 ride tickets.

'cause so much cell division has occurred between single cell embryo to a [00:13:00] newborn baby. We've done, we've used up half our tickets already. But then the problems doesn't stop there because we still have a lot of growing to do, wounds to heal, infections to fight. Lots of cell division still has to occur.

And when we run out of our last tickets, that's when we lose our ability to function. We die of about age. And, and that's, that's a fact. That's, we can't do anything about that. And, well, not before I started doing my research. That is, um, we are our lifespans and if you had the perfect genetics and the perfect lifestyle.

This clock, by the way, it's called the Hayflick Limit. It was discovered by Leonard Hayflick. The Hayflick limit is the thing that tells us how many times our cells can divide before we run outta ride tickets. That if we have the perfect genetics and lead, the perfect lifestyle, that limit are lifespan to a maximum 125 years.

There's no way to live longer than that, and I'm trying to, I'm trying to fix that and [00:14:00] because it took me so long to understand that it was telomeres, there was this clock that was controlling this clock. I went in after I got my PhD, I went into biotech and use my arsenal of all these tools for a whole bunch of DI diseases.

And I actually, I mean, if you look at my track record, I'm one of the inventors of human growth hormone tissue plasminogen activator, a drug that is used for an all ambulances to treat heart attacks, erythropoietin. Which is another, it is a drug that prevents, that makes you have more red blood cells.

Beta serum, the very first drug for ever multiple sclerosis, osteoinductive factor, the first drug ever for, uh, uh, osteoporosis. Uh, I've, I've dis developed, discovered several cancer drugs. One just got approved by the FDA in the United States called Ello, R-Y-T-E-L-O. I mean, I've, I've had a very successful career and [00:15:00] the bottom line is I can cure aging and my track record shows it.

Okay? And so, so that's what I'm doing. I am focusing on trying to find ways to make it so that we can add ride tickets back to ourselves. And, but first I had to figure out why do we, why do we lose 'em? And the. The thing that back in the 1990s when I first learned about, uh, telomeres, that they shorten and we can actually measure 'em and determine how old a person is and more importantly, how long it'll be before they die, about age better than any palm reader can.

Uh, we, we, uh, I I realized that if every time a human cell divides and the telomere get shorter, how can, how is it possible that our children are born with longer telomere than we have when that all requires cell division to do reproduction? And so back in the [00:16:00] 1990s, that's what our focus was on, is finding out why don't telomere shorten, why don't those cells use upright tickets when they divide?

And what we discovered was this enzyme called telomerase, and it's only found in our reproductive cells. And so every time a. Reproductive cell divides. The telomeres do get shorter, but then ERs comes in and re lengthens them. It's like a tug of war. Okay, so you got the cell divides, telomere, shorten p people pull on the telomeres to shorten 'em, imaginary people inside our cells, and then right afterwards ERs comes in and re lengthens it.

So this is back and forth. So it's a tug of war. It's a tie. The problem is that in all of the other cells of our body, we just have the shorteners because the gene, if, if our reproductive cells produce telomerase, that means all of our cells have the gene for producing this enzyme called telomerase. It's just [00:17:00] shut off and it's, it's shut off.

The only reason to shut it off is, as I mentioned before, is a way of eliminating the longer lived. So that the offspring can interbreed okay. To increase diversity within the species. So it turned out any species that figured out a way to eliminate the longer lived had a better chance of surviving rapidly changing environments, and therefore they, they had less chance of going extinct.

And that's why most species now have a, an aging process. But, uh, so, so we, we discovered this enzyme and so in the last 30 years, all I've been doing has been trying to figure out ways of turning the gene on. Okay. Either by, uh, finding, well, mostly by finding supplements or chemicals or molecules or nutraceuticals that when get inside of our cells, we'll go to that gene.

The tel gene [00:18:00] and actually turn it back on. Um, I mean, every gene in our body, we have 25,000 different genes. The ones hair color, eye color, all this kind of stuff is controlled by genes. They're all controlled by dimmer switches. Okay, so like a dimmer switch. They, they're called promoters. Okay. So there's a promoter and that's attached to every gene, and it's like a dimmer switch.

And it, and, and for some reason this dimmer switch, and I, for some reason, I know exactly why, because I just mentioned it, but it's, it's turned off. So I'm looking for, and it is turned off by a protein called a repressor binding into that dimmer switch and turning it off. And so I'm looking for nutraceuticals or chemicals or molecules that will get inside of our cells, bind to that repressor and dislodge it and turn that gene on.

And so I started Sierra Sciences 25 years ago. Just to focus on, uh, [00:19:00] finding ways to do that. We have million dollar robots dollars in US dollars, uh, that that can screen up to 4,000 different, uh, nutraceuticals chemicals a day and, uh, uh, identify these things. And out of like probably a million different things that we have tested so far, we've only found like 50 nutraceuticals that actually do, uh, turn on the gene.

And, and it is actually, when I say nutraceuticals, I'm how can only about fractions. So we, we take a plant extract, there's too many molecules in a plant extract. There's like over 200,000 different types of molecules in a plant extract. When you have this, that many molecules, you're, yeah, some are gonna.

Dislodge that repressor and turn the gene on. But then some are gonna, some other molecules are gonna inactivate that molecule that turned the gene on. So, so you have to, you have to reduce the number of molecules. So we [00:20:00] fractionate the plant extracts into smaller groups, uh, called fractions, and maybe at the most they'll have 10,000 different molecules.

And so out of testing like 600,000 nutraceutical fractions, we have found 50 that, uh, actually do cause that repressor to be dislodged. Now, as I said, it's a tug of war, so we haven't won the tug of war yet, but we've slowed it down. So we have the people pulling to shorten your telomeres. Now we've added some people to lengthen the telomeres, but we're not winning the tug of war yet, but we are slowing it down, which is a really good thing.

Uh, we just have to, uh. Uh, continue our research to find more and more potent telomerase, inducers they're called, uh, but I, I'm, lemme just do a plug really here, 'cause I got it right here. The five top nutraceuticals that we've discovered are in this product called Tele Vital, [00:21:00] uh, that's sold by a company called Touchstone Essentials.

Uh, and it's, it's Televi, it's USDA. Lemme see if I get this in the camera. USDA, uh, organic. It, it's, it's the most potent polymerase inducer on the planet right now. Um, but I'm just a research, my company's just does research. So we discovered those ingredients and we licensed 'em to this company, touchstone Essentials.

Uh, and they've, they've turned it into a product and marketed it. Um, but, uh, it's what, what I'm hoping is that within three years we can have something potent enough to actually win the tug of war. Fortunately, I've been saying that for 20 years, and, uh, it, uh, there's a whole subject I'd love to talk about.

It's like, why, why has all this stuff taken so long? Why has cancer not been cured yet? Yeah. Why has heart disease not been cured yet? Why has Alzheimer's not been cured yet? And I, why hasn't agent been cured yet? [00:22:00] And, and I can, that's something I'd really like to talk about today, if that's a, there's time for this.

Mehmet: Be before I go into this, just out of curiosity and, and ignore if I can use some wrong terms here or like, uh, I might miss things up. I'm very transparent with my audience. You know, when I'm not the expert, I tell them I'm not the expert. I'm telling you also, bill, when you talk about fighting these chemicals or, um, you know, components that might help how, making sure that.

This is gonna work, happens like, okay, I know a little bit about how they do drug discoveries and they go to the FDA in the US and they start the trials probably first on animals, and then they have the human trials. And I'm talking here about curing things like, I don't know, high, high blood pressure, [00:23:00] uh, you know, like everything related to, uh, sugar blood, blood sugar and, and these kinds of things that you can track actually, when it comes to aging, which is sometime we might need to wait for long time h how the trials work.

How, how, how you know that this will work. 

Bill: For bottom, for first, you cannot measure aging. Uh, you can, it's like you can, we all know what aging is. Okay? We can walk down the street and we can look at people and we can estimate their ages. So we know what aging is, but it's not measurable. There's no quantitation, there are biomarkers of aging, um, like, uh, including telomere length, but there's also DNA methylation and IgG glycosylation.

There's also grip strength. There's all kinds of things, but these are all biomarkers of aging. And if you reverse the biomarker, that doesn't mean you reverse aging. It just means you reverse the biomarker. [00:24:00] So it's, it's about all about how do you gauge your success? And I say, you know, aging's not measurable, but we do know what aging is.

And I call it, I call my gauge of success, the Betty White Test. Okay? I would show pictures of Betty White when she's 25 and 85. And I wish you hadn't passed away because I would've loved to have turned her back into a 25-year-old. But, uh, I say that nobody has actually come up with a cure for aging unless they can make somebody pass the Betty White test.

And that means going from looking and feeling and behaving like 85 to looking and feeling and behaving 25. And we can't measure that. We can't say, okay, there's, there's no quantitation. All we can say is we can qualitatively quantitate. And so we give those QQ scores for qualitative quantitation. So when we, so you can, you can take a bunch of people, you can have, you can have a, have an audience [00:25:00] of people then rank these people in order of age.

You can't put numbers on it, but you can get 'em in the right order. And so you can give 'em a QQ score. This person's QQ score is higher than that person's QQ score, that kind of thing. So, 

Mehmet: right. 

Bill: So that's the only measurement there is, but. We can't use that for clinical studies. So what we have to do instead is we have to treat an aging related disease like Alzheimer's.

Mehmet: Mm. 

Bill: Okay. So we've already done mouse studies and we have shown that lengthening telomeres in mice and engineered mice. 'cause as I mentioned before, rodents don't age by the way humans do. They don't age by telomere shortening, but, but we have engineered mice that do. And when they got old and started having dementia, like couldn't remember how to go through a maze, we found that lengthening, the telomeres actually allowed them to remember how to go through the maze again, which is [00:26:00] telling us that dementia is not the loss of me memory, it's loss of access to the memory.

So lengthening telomeres restored that access. Okay, so now, so what we would do is we and I do have human clinical studies trying to get underway. Right now they're just super expensive to try to reverse Alzheimer's. And, uh, it's, um, the idea is that we would reverse it and we, we'd treat people, show that they, you can measure Alzheimer's.

We can, there's lots of different tests for measuring that. We, we, we can show that their cognitive skills came back, but lo and behold, they passed the Betty White test too. Okay? And so that's, that's the way to get around the fact that we can't legally, or not legally, but effectively do clinical studies 'cause there's no measurement of aging.

But everybody will know when, if, if, let's say we were treating Betty White, who, you know, as 95 or a hundred when she passed away, [00:27:00] if all of a sudden she walked out on stage and looked and felt and behaved 25 again. Everybody in that audience would know that. Okay. And so, but, but that would be we, we, we, that's, we, we would just be able to do that and then everybody would want to take this treatment.

And, but, uh, uh, we would have to start off with, uh, testing for an age related disease. And there's, there's a lot of them. Okay. Osteoporosis, including Alzheimer's, uh, even wrinkled skin. Okay. That, and hair color, all those kind of things can be tested, could be, uh, looked at, 

Mehmet: right? I can ask you, you know, because you, you mentioned you want to talk about like why we didn't cure, for example, Alzheimer, why didn't cure cancer?

But to put some context, which I, I found a way to relate things. Hopefully I'm doing it the right way. Um, I spoke on this podcast also with, um, some folks who are in the bi biotech, um, and they talk about the [00:28:00] biomarkers. Some people, they talk about the lifestyle. Some people they talk about genetics. You know, we, we have this famous joke sometime, I saw it some, somewhere on the internet.

I can't remember where they show like a, you know, someone who crossed hundreds, uh, maybe he's 105, but you know, he, he's still smoking, drinking, and he's healthy jumping dancing. And I know like this is, go in, in kind of a f clore kind of way of thinking. But this brings the question is what's again, I'm going, you know, maybe it's a rabbit hole about why we didn't cure cancer, why we didn't cure a lot of other diseases, which we know about.

They, they are with us for a long time and we, we, we, for example, I gotta give very simple example. Like, if you don't do this, um, like you are in a better situation not to get this [00:29:00] disease, let's say. I dunno if if you, you, you're not like under the, uh, the sun for a long time, like the, the chances that you would get, um, a, um, a skin, a skin cancer will, will decrease, right?

If you don't do this, like, your chances of not getting X will decrease now. But we, we know that sometimes it happens, sometime they say it's genetic. I'm not the expert. But why wouldn't, and correct me if I'm wrong, like if we don't know, really, we know what happens. We know what cause cancer. We know, like the behavior, we know, like the cells goes crazy.

Like just to make it simple to the audience and they start to behave in a way which is, you know, they shouldn't behave this way. Here I want to ask you, like building on what I mentioned now, bill, why we were not able with all these advancements in biotech, in, in, we have now AI also as well. [00:30:00] Um, why we still, um, struggling in 

Bill: this?

Well, lemme just first say we've had AI since the 1970s. I, I was taking classes in artificial intelligence in the mid 1970s. Uh, so it's, AI has just gotten better as a function of Moore's law. So there's nothing new about ai. But, but the thing is, and, and I have, I've written my own AI and we have AI here at Sierra Sciences, but the, uh.

First of all, let me make another comment. So some people will have, uh, get skin cancers from sun exposure and some won't. Okay? But that's because of our diversity within our species. We're all different, okay? 

Mehmet: Mm-hmm. 

Bill: And, uh, but even though we've been doing this biotech and technologies and stuff like that forever and ever, the, it's, it's, it comes back to the how do you gauge success, okay?[00:31:00] 

And so, let me, lemme first say I am not, my company is not competing with anybody. We are working with everybody. I mean, I want my aging cured, even if I'm not the person that cures it, okay? I want my cancer cured even if I'm not the person that cures it. And if I ever get cancer, knock on wood, um, I, same with heart disease and inflammation and Alzheimer's and all this kinda stuff, I want the cures.

And I am, I'm working with everybody. I collaborate with everybody. You, you'd find that other people in the field are really surprised that I'm supporting them, sometimes even providing them with funding. Um, but here's the problem. In, in the academic world, the gauge of success isn't how many diseases they have cured.

It's how many publications they got. Okay. Because in order to get funding in academia, [00:32:00] you have to get grants, government grants, or other kind of grants. And how do you, how do you get grants? Well, when grant reviewers are looking at grants, they look at how many publications do you have? And so there's a term called publish or perish.

And so academic labs are more focused when they get grant money, what they do is make a list of all the different publications they're gonna get out of that grant money. So. When they run outta grant money, they can get another grant. So the focus is on how many publications can you get, and 99% of the time, the publications really are meaningless and they're just, look at what I've done.

Look at me too. I've done this experiment. Things like that. So that's the problem with academia and the commercial world. This is one of the reasons why I went into the commercial world instead of staying in academia, is because I was too shocked at how much emphasis was on just getting publications, [00:33:00] regardless of whether things worked or not.

And sometimes you would, you would, you would all do all this work and conclude that it didn't, something wasn't going the way you wanted. So you say, well, let's at least get a publication out of it. So you publish it anyway and it's pointless. But okay. So I went into the commercial world instead thinking I could get out from under that.

But then I learned that, that in the commercial world, it's all about. Quick return on investments. Okay, so gage's success in biotech is how fast investors can get quick return on investments. And so, you know, I had no problems when I started this company 25 years ago. Uh, raising funding, I raised $33 million.

I got 50 plus investors. Um, all from speaking at conferences and stuff like that and getting people standing in line wanting to invest, I was really good at it. Uh, but, uh, uh, I, I went from being a hundred percent owner of the company to being 17% of the owner of the company, and [00:34:00] I lost control. And suddenly these investors are taking over my strategy meetings, telling my scientists to work on other things, to bring quick return on investments for them.

And they said, we'll get back to your curing aging later, but first let's bring in some money so the, the investors don't have to continually put in more money and stuff. So we did that. We, we got successful and the investors said, well, look at Bill Andrews me has in, has added value to the company so much so that let's sell the company for a profit.

And I was devastated by that. And I've seen this happen with all my friends that started, other companies, colleagues that I was working with, collaborating with. Everybody was having this problem. 'cause the investors were only interested in making money and, and they didn't wanna wait for the big cures because that would take too long.

They wanted quick return on investments and that was their gauge of success. [00:35:00] I was lucky, I ended up being able to orchestrate a complete takeover of my company. Buy out all the investors, and now I'm a hundred percent owner of my company, but I refuse to go with traditional investing anymore. I, I would not, if, if I'm talking to somebody that's interested in investing and they, they say to me, well, how long before I'll get a return on my investment?

I'll say, sorry, you don't qualify. You know, I just would not allow that kind of person to be involved. I, but if they said, how long will it be before you can cure aging? That's the kind of investor I want. And they don't exist. I mean, even, okay, so the third category is these celebrity billionaires. Okay.

That have started all these biotech companies, including in like, uh, evolution. Okay. Which I'm sure you're familiar with in Saudi Arabia and stuff. Um, they're all focused on notoriety. Okay. It's like, uh, and, and the proof of that is why do you even know about them? It's because they're trying to. [00:36:00] Advertise themselves.

They're trying to promote themselves and they're hiring celebrity, uh, advisors. The advisors are hiring celebrity scientists and as a result, none of these celebrity biotech companies are getting anything done. There's nothing accomplished. And so, like, my question always is what is your track record?

Okay. And most, when, when you ask one of these famous scientists that are well known that you hear all the time talking on talk shows and things like that, you ask 'em, okay, what diseases have you cured? Well, I haven't cured any diseases yet. You know, they're just all talk. That's what all of 'em. But you look at my track record, and I already mentioned all the diseases I have come up with cures for, and this is why I'm gonna get something done.

But. Investors don't want to invest in me because I [00:37:00] refuse to do quick return on investments. My investment, I, it's gonna, if I, if I had all the money I needed to cure the aging process, I could have aging cured in three years. Okay. But I've been saying that for 20 years, and it's because every single person that I talk to, including, I've had every celebrity billionaire sitting in my conference room here, I'm right across the street from the airport.

They'll land their 7 47 jets right across the street and walk across and meet with me. But I just won't accept money from 'em because they have these outlandish, ridiculous things where I lose control of the research and they suddenly turn me into somebody that's gonna just make them quick return on investments.

Even though they have more money than they could ever need, they still are. Their mind is set on making more money. I think the only way that we are ever going to cure cancer, heart disease in inflammation, and I'm talking about all my colleagues too. I, I'm not just [00:38:00] trying to bring in money for myself. I want, if I, if I came up with a lot of money, I'd make certain, all my colleagues got some of that too, because I, as I said, I want my own aging cured, um, even if I'm not the one that cures it.

But I, I think the target has to be these, um, uh, very discreet, high net worth individuals, ultra high net worth individuals that just by their definition of being very discreet, you have no, uh, it's really impossible to reach them or anything like that. I always, when I speak at medical conferences, I always say the one and only people in the world that these.

Very discreet, ultra high net worth individuals have to communicate with are their doctors okay? Because they, they still get cancer and heart disease and their loved ones still get cancer and heart disease and Alzheimer's. So they have to see their doctors. And I, I'm, I, I'd say the doctors are the ones that have to tell these very discrete, ultra high [00:39:00] net worth individuals that these diseases are not gonna get cured unless they step forward and start supporting the academic research, the commercial research, all the research going on that are trying to cure diseases that they can't get funding.

Because curing diseases does not, repo, not, not provide quick return on investments and does not, does not involve getting scientific publications. And so we gotta find a way to, to get these diseases cured without having those gauges of success. Interfere. The gauge of success has to be how many cures, how many diseases have to be cured.

We gotta get away from people that are focused just on making money. I am not in it for the money. And I, my colleagues that I really work closely with, they're not in it for the money they're in. It just 'cause they want the world to be happier and healthier and cure all these [00:40:00] diseases that make life less lovable.

I think living's the greatest thing that ever happened to us. I love living and I just hate the fact that living can become any less lovable for any of us just because of these dumb things that affect all of us. And most people aren't even aware of how many people are sitting in hospices and nursing homes and assisted living homes that can't take care of themselves anymore.

They're depressed, they're unhappy, and the rest of us just keep going on thinking. Well, we'll, we can work on trying to figure out cures later on. Right now I want to focus on bringing in more money so I can enjoy life more. But you know, it's just when they, when they finally get around to saying, oh, well now I wish somebody would cure my aging.

Now I, I'm ready to invest money into curing aging. It's too late because they, you know, it takes years to actually, actually come up with a cure for aging. As I said, I think if I had all the money I would need, and I, I, I estimate that to be like [00:41:00] $130 million, uh, based on extrapolating from all the previous work we've done.

Uh, if we had $130 million, I could have a, uh, drug or a nutraceutical or some kind of therapy that would actually cause us to actually lengthen our telomeres and cure aging. Now, that might not be the only key thing that needs to be done to cure aging, but I can tell you this much. No matter what else we do to try to cure aging, aging will never be cured unless we also solve this telomere shortening problem or the hayflick problem.

Hayflick limit problem. 

Mehmet: So, so still we have long way to, to solve this, uh, mystery. I would say just two things from what you mentioned, bill. Um, I'm still surprised that, yeah, to your point, like, you know, because when you say investment people, they say, what's the return on investment? And [00:42:00] I don't know why.

You know, it's their mindset. Even in biotech that things can move fast. Hopefully we will have, like, I'm hoping we'll have what we call them, the impact investment, uh, thesis based, um, you know, investors who, of course they look for the return, but they look for the impact because, you know, um, at the end of the day, it's not always about this.

And one thing which I believe in is that many times, which is, I hope people will get it. Sometimes you, you put a lot of money on a research, and I know this from different fields, and then out of these researchers you come out with some other things that actually not related to what you are doing, but they become like mainstream things and you know, like we know like.

For people who are familiar with tech, like back in the seven sixties and, and seventies company, which is Xerox. They used to have this, you know, r and d and they came out with a [00:43:00] lot of things which not related to their core business, which was printers. Right. And they invented a lot of things over there.

And if someone would ask about the return on investment of a mouse, I'm talking here about the computer mouse by the way. Like, I, I wonder if someone have asked like, why you invented this? And probably no one saw at that time, what could that be? But it river did the revolution in, in the computing industry.

The second thing from what you said, and this is a question, um, I'm not, and I'm not familiar again, I'm curious to know from you, because you've been doing this for a long time, um, when we talk about attempts to cure these diseases, um, wouldn't that also. Make some of the pharmaceutical companies raise their eyebrows and say, Hmm, you're coming after my, you know, main bread and butter area.

So probably they would try. I, I'm just, [00:44:00] again, I'm not into conspiracy theories or anything like this, but, you know, where is the defensibility for pharmaceutical companies in this case? 

Bill: Well, let me address the first thing you brought up first. Yes, sure. In, in, this is one of the reasons why I left. I, I've been working at large pharma companies before I've been, uh, directors in the companies.

I've been the CTO Chief Tech Technical Officer for a company about large biotech company. The problem is, yes, we do all this research and we accidentally come up with a discovery that we didn't expect, and the company and the investors in the company will say, well, look, we can make money off of that.

And they say, stop everything else you're doing and focus on that. Okay, even though we might be working on a cure for disease, they suddenly think, no, let's work on this thing to make a lot of money. And I, I'm gonna mention a name and that's Geron Corporation. I, Geron Corporation [00:45:00] was, their name is short for gerontology.

They, they were focused on curing aging and I went to work with them when they first started working, but it suddenly started becoming obvious that it was also, I discovered some things that turned out to be great ways to cure cancer. And they told us one day to stop all work on aging and focus on just the cancer research.

Now I was already national inventor of the year for my cancer research in the United States. Okay. Uh, and you know, I'm very interested in cancer, but I think the number one cause of cancer is aging. I think the way to tackle, uh, cancer is to cure aging. But the Geron Corporation told us to all stop working on aging and focus on cancer because of these discoveries that I'd led the research on to make.

And I, I left, I, I, I couldn't, I couldn't tolerate that because I'd seen that happen at previous [00:46:00] companies. I'd worked at Burle Biosciences and Koon Corporation. They seem to be so focused on what, what's gonna make us more money do this or that, whatever, whatever makes us more money. Let's do that. And I was always focused, I've always been focused on trying to cure diseases.

So when this happened at Jeron Corporation, when they told us to stop working on aging and focus on cancer. I had already had a very illustrious cancer background. I left, I left Gerron, I resigned, and I started my company, Sierra Sciences to focus just on aging. And, uh, so that's what I've been doing. But we actually have projects here that are probably the best project ever for curing cancer and also diagnosing cancer.

Uh, and, uh, you know, as, and these are quick return on investment things that people could invest in if they wanted to. But my focus isn't on trying to, uh, focus on that. I'm trying to focus on the aging because [00:47:00] I believe that aging will cure cancer anyway. Or curing ca aging will cure cancer anyway. Uh, and, uh, but yeah, so that, that's the answer to the first one.

Yes, it is too much. The pharma companies are too focused on. It's not the company's, the investors. They're too focused on how can we make the company make money. Okay. So the, uh, the second part of your question was what ab what about these large pharma companies that look at us, like companies like mine as if we succeed that we'll put them out of business?

Yeah. Well, that's a big problem. Okay. I mean, I've had Johnson and Johnson here, I've had Merck here. They're, they're all interested in, in my research. But after talking with 'em for a while, I get, I start realizing they're, they're not interested in me succeeding. They're interested in getting control of the project and shelving it.

[00:48:00] Okay. I, I am so I don't, I, I won't work with these companies. Uh, it's, um, and, and a good example is Procter and Gamble, when I was promoting a pet product. Okay. Um, they, uh, they, they, they actually said to me, well, we don't see a, a market for extending lifespan and healthspan in pets. And so, but they said, but we'll, we'll invest in you.

And it is like, well, you can't say that and then say, you're gonna invest in me and expect me to say, sure, I'll take your investment. Because I, I, I knew that they, all they were gonna do was shelve everything we're gonna do. But, uh, I, the good thing is I have found people now. That do want to create pet products outta my research and keep an eye out for something called telo dash TELO dash, and then the words DASH, uh, because that's a product that's gonna come out soon [00:49:00] that's gonna extending lifespan and healthspan in our dogs, cats, and horses.

Okay. Wow. But not our rodents, our rabbits and our mice and our rats are not gonna benefit from it. 

Mehmet: I, I care about cats, 

Bill: cats, cats, dogs, horses, sheep, pig, and deer also. And primates, they all, they're all gonna benefit from this product and it, it, it should be launching soon. I'm, I'm actually meeting with the, uh, woman who's heading up the company that's gonna do that, uh, uh, uh, next week.

Uh, and so, um, I'm gonna get an update on that. So I'm looking forward to that. But I think the truth is people spend more on their. Pets health than they do on their own health. 

Mehmet: Yeah, true. 

Bill: So Proctor and Gamble telling me that, uh, there's, there's no market in it. That was complete nonsense. Okay. Uh, and, but, but yeah, I, I think, I think this is gonna be a great product and I look forward to, and, and [00:50:00] so, you know, this company that is gonna be launching this product, they're looking for investors too.

So if anybody is interested, get in contact with me and I'll put them in contact with them. Um, but, um, and that's, that's a case of quick return on investment. That's, you know, so, so whatever. Um, but uh, yeah, it's, it's, it is the big pharma companies. You know, it's like, okay, here's a really good example, and that's the COVID vaccines, okay?

Mm-hmm. Um, I mean, okay, so I, I've invented several vaccines and when I listed all the, my discoveries, I forgot about mentioning several vaccines that I've developed, uh, for curing pneumonia and, and dysentery and things like that. Um, so I do know a lot about how do vaccines work, but the vaccines, the DNA and RNA vaccines that were made there, there's a terrible flaw with the these that nobody out.

You never hear this one from [00:51:00] anybody else. Okay? But I'm gonna tell you, when you get treated with a vaccine, what you're doing is you're injecting a protein or molecule called an antigen. 

Mehmet: Mm-hmm. 

Bill: And that antigen gets inside your blood. Induces an immune response. Okay. And so you build antibodies against that antigen?

Well, in order to do that, the antigen has to be in the serum of the blood, not inside the cells of the blood. Okay. Because if the protein is inside the cells, the cell wall shield shields those proteins from the immune system. So the RNA and RNA and DNA vaccines, what they do is they all elect viruses that get that go inside the cells and then produce the antigen inside the cell, which makes no sense because how's the immune system gonna mount an immune reaction against a protein that's built [00:52:00] inside the cell?

But the only way it can is if some of these cells break open and release the contents into the, into the serum, which is a very inefficient way to induce an immune response. People keep wondering why are so many people vaccinated for COVID vaccines but still get COVID? Okay. And that's why it's because the immune system is very inefficient.

Plus there's a whole bunch of other side effects from the delivery systems for putting, uh, RNA or DNA inside of cells that's causing all these long COVID problems too. But there's been companies that have come up with traditional vaccines for producing, uh, to delivering the antigen to the serum, and they could never get a foothold in the market because those big four companies, Moderna, Pfizer, I forget the other one's names John, uh, I forget who the other ones were, but they all [00:53:00] block.

Those companies from being successful because they wanted their vaccines to continue to make them money. Okay. So their COVID vaccines that their vaccines, they're cheap to make, they were quick to make. It was a opportunity for big pharma to make a lot of money by coming up with these really fast vaccines that by their nature of being fast, they're also very inefficient.

Uh, and you know, you hear complaints all the time, but you've never heard the complaint I just gave. And I don't know. 'cause mine's based totally on science. The science of the logic of, of the vaccines. Uh, besides the long COVID problems, there's also the logic of the actual inducing an immune response makes no sense at all.

There was also a study that came out that showed that the spike protein contains a domain in it that actually inhibits. The immune system of creating antibodies [00:54:00] against it, and that's, it inhibits something called the non-homologous enjoining enzyme called NHEJ for short. And this, the non-homologous enjoining enzyme is an enzyme that actually shuffles the VD and J regions in our chromosomes that create the part of the antibody that recognizes the antigen.

By shuffling different things, it inhibits that enzyme. Okay? So other companies have come up with ways of destroying that inhibitory domain in the spike protein, and therefore let's immunize people with a spike protein that doesn't have that domain. But they too couldn't get a foothold in the market because the big companies that already have vaccines.

Blocked them, did everything they could to prevent them from being successful so that they could continue making money. This is so, you're right, this, this [00:55:00] problem at Big Pharma is a big problem. And my solution is if I, I, I'm saying to myself that when I have a cure for aging, I don't need to have marketing.

I don't need to have ma money. I, I just need to have somebody, I wish Betty White was still alive. I just need to have somebody like Betty White walk out on stage and look 25 again and people be knocking on my door trying to get this treatment without any marketing at all. Um, and so, you know, setting up on some island in the middle of the Pacific, just make certain there's a runway and people will be landing their airplanes just to come and get treatments.

Uh, it, it's. And plus I'm not in it for the money. I, when I come out with a cure for aging, I really just want to drop it from airplanes. Okay. Get provided to everybody. Okay. And, you know, shoot, that's like throwing money away. But I, I'll make a living off of speaking tours. You know, that's the way I look at it.

I'm, I'm not in it for the trying to make money. [00:56:00] And investors hate that when I say that because why would they invest in somebody that's not interested in making money? Well, I think the number one return on investment is the humanitarian return on investment, not the financial return on investment. So I am looking for funding sources that are more interested in the humanitarian return on investment, more than the, uh, financial return on investment.

And those people. They don't know 'cause they're sitting on their million acre properties somewhere in the world, their islands and things like that. Completely limit isolated from everybody else. Having other people do all their work for them and things like that, which I'm jealous of. I, I think that'd be fantastic.

But, so I'm not complaining about them, but they think that everything is under control. They think that people are working on curing these diseases and they think the reason [00:57:00] why the diseases aren't being cured is because of the science is too hard. But I know people that have cures for pancreatic cancer.

I know people that have cures for Alzheimer's, people that have cure for strokes. I'm a scientific advisor volunteer. I'm a volunteer scientific advisor for several companies that have really great cures. They cannot get funding, not even grant funding, because they don't have publications, but they have the cures and it's just so frustrating.

That's why we need a call to action. We need to find a way to get to these very discreet, ultra high net worth individuals and let them know that their loved ones and themselves, they're gonna die from Alzheimer's and cancer and heart disease because they aren't coming forward to help in developing the cures.

And if, and, you know, we're not, when they have, some of these people have a trillion dollars when, when they have a trillion dollars and they have to spend [00:58:00] like $200 million on getting a cure. That's, that's. Not gonna affect them one bit financially. Okay. They just don't know it. Okay. And that's what we have to find a way to let them know this, because that's, that's the only way the world needs to know.

That's the only way that diseases, cancer, heart disease, everything else is gonna get cured. And period, 

Mehmet: maybe they are acting selfish. I'm not sure. Because they want it only for themself. And this is why maybe I, I, I, I don't know. Right? So, but I have heard it somewhere. I read it somewhere. Especially these people who are into this, uh, biohacking and, uh, age reversal kind of stuff.

Um, they talk like how these super billionaires, they have their secret labs and you know, they, and yeah, I wonder why they don't want to share it. Like, like, okay, I understand you, you want to stay healthy as [00:59:00] long as possible, but why not with other people? And I think, you know. Your point is very valid.

Like, I think everyone will benefit. If I think about it from, I gotta put, I'm not, I come from a engineering background, but I gotta put an an economist hat on me. If people are healthy, actually this is also good for the economy and it's good for everyone because they're gonna go out more, they're gonna travel more, they're gonna spend more time with their loved ones more.

Um, so everything will be booming because, you know, and, and this is the also sometimes I see in some economies where they talk about, you know, the aging problem and we have like more old people than young people. And, you know, the government's gonna pay because they need care. And I think it's the, you know, and I think now about it from this perspective you just described, I think it's beneficial for everyone.

Like, I, I, I, I wouldn't understand why someone wouldn't invest in it. 

Bill: Well, no, that's, I, I have had [01:00:00] these billionaires okay, here, the, these, these ones that have started their own secret companies to start doing things. 'cause I'm well known. Okay. I speak at, I'm keynote speakers at conferences all over the world.

I've been in Dubai a few times, speaking at conferences there. They, they know about me, but they come to me and they, even the billionaires, they say, well, how long will it be before I get a return on my investment? You know? And it's like, it is like complete nonsense. They, they're so focused. But then there's a few of 'em.

I, I've been talking to these billionaires for 20 years or more. There's a few of 'em that have come forward and said, okay, I'm ready to start doing something because now I've been de detect, I've been diagnosed with Alzheimer's, and so I need to get this cured thick, uh, disease cured, fixed, but then they die right away, you know?

And I've, I've seen so many of these super wealthy people. That could afford to have developed a, invested [01:01:00] in a cure for their disease. They die before they actually get a chance to do it. And I, I mean, I don't wanna mention names, but there's, you can I, you know, there's fewer billionaires that haven't been here than that have been here.

Okay. So if you think of it like a billionaire that's passed away from a disease that could have been cured, like cancer or something like that, believe me, they, they were here talking with me. Okay. They just, they came too late, you know, and that's why we gotta let people know it takes a while to cure diseases.

And plus, even when you do come up with a disease, everybody's afraid to be the first to try it. Yeah. Here they want somebody else to be treat first and then so. You know, we'll do things like treat people, but then before that study gets done, the person dies. You know, it, it's, it's, it's such a ridiculous, the system is broken [01:02:00] and I seem to be the only one that seems to be aware of it.

And I'm trying to just really educate the world that we have to change if we want to, um, cure diseases. I, I've, I've tried everything. I've tried go-to market partners. I do have a lot of go-to market partners. Like I showed one, this tele vital company, this tele vital being sold by Touchtone Essentials that actually provides a royalty that I use to fund my research.

Okay. And there's other companies too. Uh, company called One Truth 8 1 8, and another company called Defy Time. There's, there's a several companies that, that actually sell products that I discovered the ingredients of. I don't get into the marketing, but I, but because I dis, I license the discoveries to them, they pay me a royalty, which funds our research.

That's how I get my research done here as opposed to fund investors. I don't want to bring in investors and lose control. So I get my funding from go to market [01:03:00] partners that don't exert any control over our research. But, uh, it's like that doesn't even work 'cause it doesn't bring in enough funding to do the research.

I, my research costs $2 million a month to do, and the only way to really get that kind of funding is to, uh, find some like very discreet, ultra high net worth individual that, that believes that I can cure diseases and my track record shows I can and needs me to cure diseases because they have loved ones or themselves are worried about aging, cancer, heart disease, things like that.

Uh, it, it's. It is crazy. Um, it's, we, I, I don't know how to make it work, but that's what we gotta do, is we gotta make it work somehow. 

Mehmet: Right. I think you mentioned a few moments ago, like about the marketing. I think we don't, uh, want marketing, we want awareness to your point. And awareness is Yeah, like, um, uh, hopefully I would be able to contribute even like on, uh, [01:04:00] the nano scale of, of, you know, the whole world probably, um, by trying to, to spread the message, uh, you know, that, that you shared today.

And I see the, uh, the, the attempt you're trying to do, which is a very noble attempt, right. To, to, to make people, yeah. As, as you mentioned at the beginning, like stay healthy as long as possible, which is for the benefit that I'm repeating myself here. It's not only on the personal level, I think like the society will benefit, the governments will benefit.

So hopefully we'll be able to get this message out. Um, bill. I'm very transparent with my audience. Is there anything that I should have asked you or anything that was on your mind you wanted to share and I didn't do so far today? 

Bill: Yeah. Well it would take us a hundred hours to discuss everything I can talk about in terms of human health and aging and stuff like that.

But people [01:05:00] can go to my website. Okay. And I make, I, so I speak at medical conferences all over the world, and Icra kind of do different subjects because I can't talk about everything in one hour, let's say. But I have these, all these different videos where people can hear me talk about what aging is, why we age, how we age, and how not to age.

In ways that you'll never hear from anybody else because all the theories don't make sense. But I have come up with using my Arsenal tools and my education I have come up with and a lot of deep thinking I have come up with ways of explaining it all without resorting to theories. Okay? Total facts. Okay.

They can listen to these things by going to my website, which is www dot sierra si, that's S-I-E-R-R-A-S-C i.com, and they'll find a button on my website called Key Videos and documentaries. [01:06:00] Uh, besides the videos of me speaking in conferences, I've also been in a lot of documentaries. Uh. Most notably the, the, the documentary called The Immortal, um, and, uh, which I'm the star of.

So it, it is like a good way to get some kind of knowledge of who I am and things like that. But, uh, uh, they can go, but people can also email me. Okay. I actually, I enjoy taking a break from the lab bench coming into my office here, sitting down, reading emails and answering questions because I know the answers and it's really easy for me to answer 'em in a way that nobody else can.

Uh, and I, I, uh, uh, so people can email me. My email address is B as in boy. So B-A-N-D-R-E-W-S at Sierra si, S-I-E-R-R-A-S-C i.com. I also wanna make a [01:07:00] point of saying I do have a podcast because of my arsenal of tools, I become very good at something that I call critical meta-analysis of peer-reviewed studies.

Which means, you know, when somebody comes out and starts making a claim that this cures that disease, or that cures that disease, I'm the person that can go and read all the papers and I can do meta-analysis, which means I make a stack of papers that say one thing and a stack of papers that say the opposite thing, and I can just count the number of papers.

And this is what a lot of people do, is they do meta-analysis and they say, well, this, this, this particular conclusion has more, many more papers than this one. So we're going with the one that has more papers. Well. That's not good enough for me. I do critical meta-analysis, which means because of my arsenal tools, I will look at the experimental design, the data analysis, the construct validity, statistical theory, uh, on and on and on.

A [01:08:00] whole bunch of different things that's in my arsenal. And some of my videos would explain all the tools in my arsenal, but I will, I will find out that after I get done evaluating all these papers, there's only one pile because there's only one right answer. Okay. So, uh, half the papers are fraudulent.

They're, they're people that just got so fed up with their research, they just got tired. They just wanted to get a publication so they could get, they get grants because of the publisher parish phenomena. So they published, even though they didn't even believe in their own results. But I will come up with critical meta-analysis.

I have a, my own podcast on that. So, so what I, when I say critical meta-analysis, is I'm taking the analysis up a notch, okay? And so my podcast is called Up One, okay? And so if you do a Google search and Touchstone Essentials is the host for this podcast series. Uh, and we're just [01:09:00] getting ready to start season two of the podcast series.

And we're gonna be looking at things like, does rapamycin really cure aging? Does exosomes cure aging? Does stem cells cure aging? All these kind of things. Um, and believe me, you're gonna hear an analysis like you haven't heard anywhere else because of my critical meta-analysis. But, uh, they can, they can go to Touchstone Essentials, they can search for up one.

But my co-host is, uh, um, Sawyer Stone, a woman named Sawyer Stone, S-A-W-Y-E-R. Stone is spelled like stone. And so look for my name, Sawyer Stone and up one podcast and you can find these podcast series. Uh, 'cause I don't, I I can also send you a link if you wanna post it on the thing. Uh, 

Mehmet: I'll, I'll take care of that.

Bill: Yeah. And, and it's just, uh, but I'll tell you my motivation is I want the world to be happier and healthier, period. Okay. And I'm not, I'm not trying to recruit people. I'm not [01:10:00] trying to get money from people except to do my research. That's the only money I want to get. I want to get this research done.

And. I wanna provide it to the, my colleagues that some people ask, why aren't they competitors of mine? Well, they're not competitors because I want, I want them to cure my agent in case I don't succeed. You know? Uh, it, it, it's so, so bottom line is, and, and I, I don't know. I'm, I'm gonna recommend maybe afterwards some colleagues of mine that I think you should interview.

Okay. Uh, 

Mehmet: absolutely. With pleasure 

Bill: and, uh, but, uh, yeah, like, well, especially BioViva. BioViva is a great company run by, uh, Liz Parrish. I mean, she's, she's very like-minded with me and she's in Seattle, Washington. Uh, and, uh, it's something like, you should get her on your show because I think you'd find her saying a lot of the same things.

I'm saying 

Mehmet: that, that would be my honor, of course. Um, well, like really one of the. Moments where [01:11:00] I feel like I did the mission is when I have, um, esteemed people like yourself who comes on the show, share their big passion and vision and what they are trying to do to get the world into a better place than it is today.

And of course, which is people live happily without diseases and being healthy with their loved ones, their families, their friends, and most importantly, it's like also taking care, love themselves, right? So this is for the sake of someone loves their body, they love, you know, to be healthy and they think what you're doing is, is really fantastic.

And I really appreciate, you know, first you came up very early. It was 5:00 AM for you for recording this podcast episode with me. So I really appreciate this. Second thing. For the links. All the links, your website, your email, the podcast. Every single link. So people they don't have to go and search around, I will make sure they will [01:12:00] find them in the show notes.

So I'll make the life easy for people and reach out to, to build, you know, I'm, I'm pretty sure, like, and I also suggest other hosts, other podcast hosts, whatever you try to cover. This is an important topic. Like this is a chronicle topic I would call it. Like we should be all together trying to, to, to add.

So thank you again, bill, for being here with me today. I really appreciate the time and I'm happy, I'm glad. Like, uh, uh, we, we made it today and we recorded this episode, and I promise maybe in couple of months we might do part two also as well to talk about the thing that you just mentioned. So happily, I would do this, I did with other guests and 

Bill: listen, help me, help, help me make it all happen.

Okay. That's all I have. Okay. Let's circulate this out. Let's get this to the world. 

Mehmet: Absolutely. 

Bill: And let's make it all happen. 

Mehmet: Absolutely. And uh, by the way, I was mentioning like it's not the first time I would be hosting someone for second, and even sometime third and [01:13:00] very soon the, the people will see an episode with someone the fourth time that appears on the show.

Happily, I do it. Like I I'm not after just like how many hosts I can get or like, you know, just making things fancy. It's about impact. This is why this podcast exists because we try to make an impact if we can do it happily. So, and this is where I need the help from my audience. So, if you just discovered this podcast by luck, you know, you are just scrolling and you just saw the CTO show and you stopped.

Give me a favor. Share it with your friend and colleagues and follow us because this is how we can reach more people like we as, as Bill mentioned, we need more people, we need awareness, and this is what I'm trying to do. So if you can help me, I really appreciate it. Also, I would love to thank all my followers, my, my audience who keep coming again and again today at the, the day we are recording this episode.

I met someone in an event and they were telling me like, by the way, we get a lot of insights from what you're [01:14:00] doing. This make me happy because that means I'm able to contribute even on a small scale. So if you're doing so, keep spreading the word, keep telling people about the podcast. I really appreciate it.

I can see the results. We are trending on the Apple Podcast charts. Of course, we keep changing countries, but since 2025 till date. Every week we are nu top 10 or top 20, sometimes top 30 in, in, in, in a country and sometime in multiple countries at the same time. So this cannot happen if you are not coming and listening to us.

So thank you very much and as I promise, always stay tuned for a new episode very soon. Thank you. Bye-bye. 

Bill: Thank you.